This vulnerability makes KEAP1-mutant lung cancer cells or tumors sensitive to glucose transporter inhibition and suggests a potential therapeutic strategy to target disulfidptosis in this subset of lung cancers (Koppula et al., 2021a). This evidence concerns the gene KEAP1 and lung cancer.